Clinical Trials
The Harold Schnitzer Diabetes Research Center is committed to promoting and conducting cutting-edge clinical research. Our goal is to enhance the quality of life of those living with or affected by diabetes
Our efforts to find a cure for diabetes, and to improve life for people with this condition, are made possible by volunteers who participate in research studies. When you volunteer, you help us answer important questions about diabetes.
Below is a list of current research at the Harold Schnitzer Diabetes Research Center. If you are interested in participating, call our research coordinators at 503 494-4704.
Current Clinical Research Studies at the Harold Schnitzer Diabetes Health Center
If you would like to be considered to participate in any of our research studies please call 503 494-4704, or complete our Online Application Form.
T1D Exchange Study
Study started on: 8/23/10
Currently recruiting patients for this study? Yes
Principal Investigator is Andrew Ahmann, MD
Currently, large gaps exist in our knowledge and understanding of the best way to manage type 1 diabetes in children and adults. The overall objective of this study is to improve the care of people with type 1 diabetes through sharing data in a common data repository. This study aims to collect core clinical and laboratory data on persons with type 1 diabetes in order to address important clinical issues, develop new research protocols, and locate participants for future clinical studies.
TrialNet Study
TrialNet Natural History Study of the Development of Type 1 Diabetes and Oral Insulin Study
Study started on: 2/13/2009
Currently recruiting patients for this study? Yes
Principal Investigator is Andrew Ahmann, MD
The purpose of this study is to learn more about how type 1 diabetes develops in "at-risk" individuals. At risk individuals are those that have a blood relative with type 1 diabetes. Close relatives of people with type 1 diabetes are being studied in three steps (phases): Screening, Baseline Risk Assessment, and Follow-Up Risk Assessments.
ITN018A Study
A Phase I Trial of Proleukin® and Rapamune® in Recent-onset Type 1 Diabetes Mellitus
Study started on: 5/15/2009
Currently recruiting patients for this study? No
Principal Investigator is Andrew Ahmann, MD
The purpose of this study is to look at the safety of using two separate drugs (Proleukin and Rapamune) in combination in people with recent-onset type 1 diabetes. These two drugs have never been used together in humans and have not been used by people with diabetes.
LAR 105 Study
A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release on Glucose Control (HbA1c) and Safety in Subjects with Type 2 Diabetes Mellitus Managed with Diet Modification and Exercise and/or Oral Antidiabetic Medications.
Study started on: 6/2/2006
Currently recruiting patients for this study? No
Principal Investigator is Andrew Ahmann, MD
The purpose of this study is to look at the safety, tolerability, and effectiveness of an investigational (experimental) injectable drug (exenatide LAR) in people with type 2 diabetes.
ORIGIN Study
A Multicenter, International, Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) versus Standard Care, and of Omega-3 Fatty acids versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in People with Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT), and Early Type 2 Diabetes Mellitus: The ORIGIN Trial (Outcome Reduction with Initial Glargine Intervention)
Study started on: 1/16/2004
Currently recruiting patients for this study? No
Principal Investigator is Bethany Klopfenstein, MD
The purpose of this study is to test if lowering blood sugar levels to normal with insulin glargine or by taking omega-3 fatty acids (fish oil pills) will prevent cardiovascular events, such as heart attack, stroke, or death in people with pre-diabetes or early type 2 diabetes.
